NEW YORK (GenomeWeb News) – Charles River Laboratories has completed its purchase of the BioFocus and Argenta service division operations from Galapagos for up to €134 million ($184 million). As part of the deal announced in March, Charles River paid Galapagos €129 million upfront and will pay potentially up to another €5 million upon the achievement of a revenue target 12 months after the closing of the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.